marked.bio

EGFR L858R degrader · degrader

CFT8919

1 active trials, targeting EGFR L858R. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of CFT8919.

  1. Betta Pharmaceuticals 1

Trials

1 of 1 trials shown

  1. A Phase I Study of CFT8919 in Patients With Advanced NSCLC

    Recruiting Phase 1 Betta Pharmaceuticals Started 2024Primary completion 2027-06 NCT06641609

    CFT8919

    …rmed locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the EGFR-L858R mutation, who have failed standard treatment (disease progression or intolerance), lack s…

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer With EGFR Mutation